Cytosorbents (CTSO) Change in Receivables (2011 - 2026)
Cytosorbents' (CTSO) quarterly Change in Receivables came in at -$67000.0 in Q2 2026, up 80.12% on a YoY basis from -$37197.7 in Q2 2025, and up 78.39% quarter-over-quarter from -$310000.0 in Q1 2026.
Powered by 
Analysis
Cytosorbents (CTSO) Change in Receivables (2011 - 2026) Analysis & Trends
Cytosorbents (CTSO) has reported Change in Receivables for 16 consecutive years, with -$67000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Receivables rose 80.12% year-over-year to -$67000.0; the trailing twelve-month figure through Jun 2026 stood at -$543000.0 (down 11.04% YoY), and the FY2025 full-year result was -$423000.0, down 124.59% from the prior year.
- Change in Receivables rose to -$67000.0 in Q2 2026 per CTSO's latest filing, from -$310000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $1.4 million in Q2 2023 and bottomed at -$1.3 million in Q3 2024.
- Historically, Change in Receivables has averaged $136335.4 across 5 years, with a median of $6500.0 in 2025.
- The sharpest annual moves came in 2022 and 2023: Change in Receivables soared 752.71% in 2022, then slumped 701.71% in 2023.
- Over 5 years, Change in Receivables stood at $428400.0 in 2022, then sank by 183.49% to -$357670.0 in 2023, then jumped by 405.03% to $1.1 million in 2024, then tumbled by 87.44% to $137000.0 in 2025, then sank by 148.91% to -$67000.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$67000.0, -$310000.0, and $137000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 386.00 Mn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 74.90 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | -224.00 Mn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 177.00 Mn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 46.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 10.20 Mn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 172.10 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | -90.00 Mn |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | -67,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -67,000.00 |
| Mar 31, 2026 | -310,000.00 |
| Dec 31, 2025 | 137,000.00 |
| Sep 30, 2025 | -303,000.00 |
| Jun 30, 2025 | -337,000.00 |
| Mar 31, 2025 | 80,000.00 |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | -1.32 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 848,330.00 |
| Dec 31, 2023 | -357,670.00 |
| Sep 30, 2023 | -668,430.00 |
| Jun 30, 2023 | 1.45 Mn |
| Mar 31, 2023 | -177,170.00 |
| Dec 31, 2022 | 428,400.00 |
| Sep 30, 2022 | -83,376.00 |
| Jun 30, 2022 | 704,246.00 |
| Mar 31, 2022 | 239,152.00 |
| Dec 31, 2021 | -698,683.00 |
| Sep 30, 2021 | -448,455.00 |